Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYP2D6 mutations and therapeutic outcome in schizophrenic patients
Autore:
Hamelin, BA; Dorson, PG; Pabis, D; Still, D; Bouchard, RH; Pourcher, E; Rail, J; Turgeon, J; Crismon, ML;
Indirizzi:
Univ Laval, Laval Hosp, Res Ctr, St Foy, PQ G1V 4G5, Canada Univ Laval StFoy PQ Canada G1V 4G5 , Res Ctr, St Foy, PQ G1V 4G5, Canada Univ Laval, Fac Pharm, St Foy, PQ G1V 4G5, Canada Univ Laval St Foy PQ Canada G1V 4G5 Fac Pharm, St Foy, PQ G1V 4G5, Canada Univ Laval Robert Giffard, Ctr Rech, Quebec City, ON, Canada Univ Laval Robert Giffard Quebec City ON Canada Quebec City, ON, Canada Univ Texas, Coll Pharm, Austin, TX 78712 USA Univ Texas Austin TX USA 78712 iv Texas, Coll Pharm, Austin, TX 78712 USA
Titolo Testata:
PHARMACOTHERAPY
fascicolo: 9, volume: 19, anno: 1999,
pagine: 1057 - 1063
SICI:
0277-0008(199909)19:9<1057:CMATOI>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
GENETICALLY-DETERMINED INTERACTION; DEBRISOQUINE 4-HYDROXYLASE CYP2D6; POLYMORPHIC DRUG-METABOLISM; DOPAMINE TRANSPORTER; PARKINSONS-DISEASE; POOR METABOLIZER; CYTOCHROME-P450 ENZYMES; TARDIVE-DYSKINESIA; GENE; SPARTEINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Hamelin, BA Univ Laval, Laval Hosp, Res Ctr, 2725 Chemin Ste Foy, St Foy, PQ G1V 4G5, Canada Univ Laval 2725 Chemin Ste Foy St Foy PQ Canada G1V 4G5 Canada
Citazione:
B.A. Hamelin et al., "CYP2D6 mutations and therapeutic outcome in schizophrenic patients", PHARMACOTHE, 19(9), 1999, pp. 1057-1063

Abstract

Study Objective. To investigate whether a relationship exists between the most common known cytochrome P450 (CYP) isozyme 2D6 mutations and schizophrenia. Because most antipsychotic and antidepressant agents interact with CYP2D6, we also investigated clinical outcomes in schizophrenic poor metabolizers (PMs) and extensive metabolizers (EMs). Design. Prospective, observational study. Setting. Two psychiatric hospitals and a university-affiliated nonpsychiatric hospital. Subjects. Thirty-nine consecutive schizophrenic patients (POP 1), 89 schizophrenics of French Canadian origin (POP 2), and 384 healthy French Canadians (POP 3). Intervention. All study subjects were genotyped for CYP2D6 mutant alleles. POP 1 patients were evaluated before and after 21 or more days of treatment with antipsychotic drugs metabolized at least in part by CYP2D6. Measurements and Main Results. Whole blood was collected to determine CYP2D6 alleles *1, *3, *4, *5, *6, and *7 using standard restriction fragment length polymorphisms and polymerase chain reaction techniques. In comparison, CYP2D6 genotypes were determined in POP 2 and POP 3. Twenty-three (59.0%)of 39 patients in POP 1 were genotypically EM homozygotes, 15 (38.4%) wereEM heterozygotes, and 1 (2.6%) was a PM. Similar genotype distributions were determined in POP 2 and in POP 3. Genotype distributions for all three, populations were in Hardy-Weinberg equilibrium (p>0.05),and there was no significant difference among them (p=0.857). In POP 1, no differences were seen among genotypes in disease symptom severity, number and severity of adverse drug effects, or attitudes toward drug treatment at baseline and at theend of the study. In fact, all patients improved significantly during their hospital stay (all p<0.05), although independent of the CYP2D6 genotype. Conclusion. Common CYP2D6 mutant alleles were not associated with schizophrenia or with disease symptoms, antipsychotic-related adverse effects, or attitudes toward treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:59:46